The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer
The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer
复制标题
DOI：
10.1007/bf02685901
复制
发表时间：
2007-01-01
期刊：
影响因子：
3.4
通讯作者：
Topuz, Erkan
中科院分区：
文献类型：
--
作者：
Karagol, Hakan;Saip, Pinar;Topuz, Erkan
背景：许多研究评价了他莫昔芬作为晚期上皮性卵巢癌患者挽救治疗的活性。在这项研究中，我们评估了他莫昔芬在我们的铂耐药上皮性卵巢cancer.Patients和方法的患者的疗效：一项回顾性分析进行了谁收到他莫昔芬在剂量20毫克，每天两次治疗晚期上皮性卵巢cancer.Results：29个合格的患者被列入这项研究。有1例（3%）完全缓解，2例（7%）部分缓解，6例（21%）疾病稳定，20例（69%）疾病进展。所有患者在开始他莫昔芬治疗后均出现疾病进展。中位无进展生存期为4个月（95% CI：2.98-5.02）。19例（65%）患者在开始他莫昔芬治疗后的前6个月内出现疾病进展。7例（24%）患者的无进展生存期为6 - 12个月，3例（10%）患者的无进展生存期>= 12个月。开始他莫昔芬治疗后的中位生存期为15个月（95%CI：7.2-22.8）。在任何患者中均未观察到他莫昔芬引起的毒性。唯一的独立预后因素，有一个显着的无进展生存期的预测值是他莫昔芬治疗的反应（p = 0.043，风险比：0.12，95%CI：0.01-0.94）。结论：考虑到最小的副作用和能力，造成客观的反应，有一个地方，他莫昔芬治疗铂类耐药卵巢癌患者。需要进行III期试验以确认药物在这些临床环境中的价值。
Background: Activity of tamoxifen as a salvage therapy in patients with advanced epithelial ovarian cancer was evaluated by a number of studies. In this study, we evaluated efficacy of tamoxifen in our patients with platinum-resistant epithelial ovarian carcinoma.Patients and Methods: A retrospective analysis was conducted of patients who received tamoxifen at a dose 20 mg twice daily for the treatment of advanced epithelial ovarian cancer.Results: Twenty-nine eligible patients were included to the study. There were 1 (3%) complete response, 2 (7%) partial response, 6 (21%) stable disease, and 20 (69%) progressive disease. All patients were progressed after initiation of tamoxifen. Median progression-free survival was 4 mo (95% CI: 2.98-5.02). Disease progression of 19 (65%) patients were shown within the first 6 mo after initiation of tamoxifen. Progression-free survival was between 6 and 12 mo for 7 (24%) patients and >= 12 mo for 3 (10%) patients. The median survival after initiation of tamoxifen was 15 mo (95% CI: 7.2-22.8). No toxicity attributable to tamoxifen was seen in any of the patients. The only independent prognostic factor that had a significant predictive value for progression-free survival was the response to tamoxifen treatment (p = 0.043, hazard ratio: 0.12, 95% CI: 0.01-0.94).Conclusion: Considering minimal side effects and ability to cause objective responses, there is a place for tamoxifen in treatment of patients with platinum-resistant ovarian cancer. A phase III trial is required to confirm the value of the drug in patients presenting these clinical settings.